These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 32164385)
1. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Doan P; Musa A; Murugesan A; Sipilä V; Candeias NR; Emmert-Streib F; Ruusuvuori P; Granberg K; Yli-Harja O; Kandhavelu M Cells; 2020 Mar; 9(3):. PubMed ID: 32164385 [TBL] [Abstract][Full Text] [Related]
2. Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway. Doan P; Musa A; Candeias NR; Emmert-Streib F; Yli-Harja O; Kandhavelu M Front Pharmacol; 2019; 10():330. PubMed ID: 31001122 [TBL] [Abstract][Full Text] [Related]
3. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M Cells; 2021 Aug; 10(8):. PubMed ID: 34440745 [TBL] [Abstract][Full Text] [Related]
4. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
5. GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma. Nguyen P; Doan P; Murugesan A; Ramesh T; Rimpilainen T; Candeias NR; Yli-Harja O; Kandhavelu M Life Sci; 2022 Feb; 291():120307. PubMed ID: 35016881 [TBL] [Abstract][Full Text] [Related]
6. Alkylamino Phenol Derivative Induces Apoptosis by Inhibiting EGFR Signaling Pathway in Breast Cancer Cells. Palanivel S; Yli-Harja O; Kandhavelu M Anticancer Agents Med Chem; 2020; 20(7):809-819. PubMed ID: 32053080 [TBL] [Abstract][Full Text] [Related]
7. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment. Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967 [TBL] [Abstract][Full Text] [Related]
8. Systemic approaches identify a garlic-derived chemical, Z-ajoene, as a glioblastoma multiforme cancer stem cell-specific targeting agent. Jung Y; Park H; Zhao HY; Jeon R; Ryu JH; Kim WY Mol Cells; 2014 Jul; 37(7):547-53. PubMed ID: 25078449 [TBL] [Abstract][Full Text] [Related]
9. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866 [TBL] [Abstract][Full Text] [Related]
10. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets. Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712 [TBL] [Abstract][Full Text] [Related]
11. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588 [TBL] [Abstract][Full Text] [Related]
13. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155 [TBL] [Abstract][Full Text] [Related]
14. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma. Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699 [TBL] [Abstract][Full Text] [Related]
15. Cross Interaction between M2 Muscarinic Receptor and Notch1/EGFR Pathway in Human Glioblastoma Cancer Stem Cells: Effects on Cell Cycle Progression and Survival. Cristofaro I; Alessandrini F; Spinello Z; Guerriero C; Fiore M; Caffarelli E; Laneve P; Dini L; Conti L; Tata AM Cells; 2020 Mar; 9(3):. PubMed ID: 32182759 [TBL] [Abstract][Full Text] [Related]
16. Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. Farace C; Oliver JA; Melguizo C; Alvarez P; Bandiera P; Rama AR; Malaguarnera G; Ortiz R; Madeddu R; Prados J PLoS One; 2015; 10(7):e0134111. PubMed ID: 26230845 [TBL] [Abstract][Full Text] [Related]
17. Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth. Olmez I; Shen W; McDonald H; Ozpolat B J Cell Mol Med; 2015 Jun; 19(6):1262-72. PubMed ID: 25787115 [TBL] [Abstract][Full Text] [Related]
18. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755 [TBL] [Abstract][Full Text] [Related]
19. Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF. Fessler E; Borovski T; Medema JP Mol Cancer; 2015 Aug; 14():157. PubMed ID: 26282129 [TBL] [Abstract][Full Text] [Related]
20. SMO-CRISPR-mediated apoptosis in CD133-targeted cancer stem cells and tumor growth inhibition. Pandey S; Lee M; Lim J; Park S; Choung YH; Kim JE; Garg P; Chung JH J Control Release; 2023 May; 357():94-108. PubMed ID: 36931470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]